Address: Đorđa Stanojevića 11d/37 (Belville)
Tel: + 381 11 63 00 685
The Inovative Drug Manufacturers’ Fund – INOVIA is the representative body of the innovative pharmaceutical industry in Republic of Serbia and was established in February 2007. Its members are sixteen leading R&D multinational companies – Abbott, Alcon, Astra Zeneca, Bayer Schering Pharma, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline, Janssen Cilag – a division of Johnson&Johnson, Les Laboratories Servier, Lundbeck Export A/S, Merck d.o.o., Merck Sharp & Dohme Idea Inc., Novartis, Novo Nordisk, Pfizer, Roche and Sanofi-Aventis.
INOVIA’s primary mission is to promote the technological and economic development of the pharmaceutical industry in Republic of Serbia and to assist in bringing to market medicinal products which improve human health worldwide.
INOVIA objectives are: Promotion of and education around lifestyle, habits and activities critical for achieving better health and quality of people’s lives; establishment of transparent, systematic, constructive and partnership like dialogue with leading governmental and non-governmental organisations in Serbia with the objective to identify and implement best-practice regulations, strategy and solutions, necessary for maximization of public health quality in Serbia and full protection of intelectual property (IPR) of proprietary drugs in the Serbian market.
INOVIA aims to establish transparent, systematic, constructive and partnership like dialogue with leading governmental and NGO institutions in Serbia with the objective to identify and implement best-practice regulations.
One of INOVIA’s initiatives was the adoption of a Code on the Promotion of Prescription Only Medicines to, and Interactions with Healthcare Professionals, which has been signed by all INOVIA members. The detailed provisions in the Code are to ensure that pharmaceutical companies operate in a responsible, ethical and professional manner. The Code covers the industry’s activities only.
Products and services